Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Bought by Linden Thomas Advisory Services LLC

Linden Thomas Advisory Services LLC boosted its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 3.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,659 shares of the company’s stock after buying an additional 140 shares during the period. Linden Thomas Advisory Services LLC’s holdings in Medpace were worth $1,548,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Centaurus Financial Inc. lifted its stake in Medpace by 2.0% during the third quarter. Centaurus Financial Inc. now owns 1,513 shares of the company’s stock worth $505,000 after purchasing an additional 29 shares in the last quarter. Lindenwold Advisors INC lifted its stake in Medpace by 1.6% during the third quarter. Lindenwold Advisors INC now owns 2,026 shares of the company’s stock worth $676,000 after purchasing an additional 32 shares in the last quarter. M&T Bank Corp lifted its stake in Medpace by 1.2% during the third quarter. M&T Bank Corp now owns 3,199 shares of the company’s stock worth $1,068,000 after purchasing an additional 37 shares in the last quarter. Nations Financial Group Inc. IA ADV lifted its stake in Medpace by 1.7% during the third quarter. Nations Financial Group Inc. IA ADV now owns 2,376 shares of the company’s stock worth $793,000 after purchasing an additional 39 shares in the last quarter. Finally, Integrated Investment Consultants LLC raised its stake in shares of Medpace by 6.0% in the fourth quarter. Integrated Investment Consultants LLC now owns 692 shares of the company’s stock valued at $230,000 after acquiring an additional 39 shares in the last quarter. 77.98% of the stock is currently owned by hedge funds and other institutional investors.

Medpace Trading Down 1.1 %

MEDP stock opened at $344.07 on Friday. The firm has a 50 day moving average of $340.33 and a 200-day moving average of $355.57. Medpace Holdings, Inc. has a 12-month low of $286.76 and a 12-month high of $459.77. The company has a market cap of $10.69 billion, a price-to-earnings ratio of 30.13, a PEG ratio of 1.77 and a beta of 1.36.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on MEDP shares. Baird R W cut Medpace from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 23rd. William Blair reiterated an “outperform” rating on shares of Medpace in a research note on Tuesday, October 22nd. Robert W. Baird increased their target price on Medpace from $349.00 to $354.00 and gave the company a “neutral” rating in a report on Monday, November 25th. TD Cowen dropped their price objective on Medpace from $413.00 to $372.00 and set a “buy” rating on the stock in a report on Wednesday, October 23rd. Finally, Redburn Atlantic started coverage on Medpace in a report on Monday, October 14th. They set a “buy” rating and a $404.00 price objective on the stock. Seven analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $380.56.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.